Faculty of Biology, Medicine and Health

The University of Manchester

  (MRC DTP) Translating genetic discoveries to improve the accuracy of predicting cardiovascular outcomes in patients with rheumatic musculoskeletal diseases

  , , ,  Friday, November 15, 2024  Competition Funded PhD Project (Students Worldwide)

About the Project

The accurate estimation of an individual’s risk of cardiovascular disease (CVD) is essential for timely intervention with preventative treatments. However, current screening tools used to estimate CVD risk in the general population, such as QRISK3, are inaccurate in individuals with chronic inflammatory conditions, such as rheumatic musculoskeletal diseases (RMDs). This inadequacy leads to a significant health inequality and epidemiological show that patients with rheumatoid arthritis (RA) have increased CVD-related mortality compared to the general population, which is particularly high in younger age groups and women. In particular, coronary artery disease (CAD), driven by atherosclerosis, often develops in RA patients up to 10 years earlier than in the general population. 

The risk factors for CAD in the general population are well established, but they do not fully account for the heightened CAD risk in patients with RA where disease-related factors, such as systemic inflammation, also play a critical role. Moreover, individual traditional risk factors behave differently in RA patients. For example, male sex and age confer less risk in this patient group. 

The differing contributions of traditional and disease-related risk factors have significant implications for the use of CAD screening tools which are calibrated for the general population. These screening tools are known to be inaccurate in patients with RA which highlights the need for RA-specific risk models that incorporate both traditional and disease-related factors to better estimate risk. 

One such approach may be the use of polygenic risk scores (PRS) which measures an individual’s inherited risk to a complex disease, such as CAD, based on the aggregation of many genetic variants. These approaches are now showing promise for CAD risk prediction in the general population and are progressing towards clinical utility with studies, and clinical trials, investigating the benefit of integrating PRS with existing screening tools to create what is referred to as an integrated risk tool (IRT).  

As PRS gain acceptance for use in the general population, we believe it is essential to evaluate the performance of PRS-based screening tools in patients with RMDs to prevent an increase of existing healthcare disparities. This PhD project focuses on developing and validating new methods for the early detection of CVD specifically tailored to patients with RMDs by combing genetic and health data science approaches. By enhancing early detection, we aim to improve preventative care and ultimately reduce CVD incidence in this high-risk population. 

https://www.musculoskeletal.manchester.ac.uk/  

http://www.cfgg.manchester.ac.uk/ 

Eligibility 

Applicants must have obtained or be about to obtain a minimum Upper Second class UK honours degree, or the equivalent qualifications gained outside the UK, in a relevant discipline.  

Before you Apply 

Applicants must make direct contact with preferred supervisors before applying. It is your responsibility to make arrangements to meet with potential supervisors, prior to submitting a formal online application.  

How to Apply 

To be considered for this project you MUST submit a formal online application form – on the application form you must select MRC DTP PhD Programme. If you select the incorrect programme your application cannot be considered. Full details on how to apply can be found on the MRC DTP website. 

Your application form must be accompanied by a number of supporting documents by the advertised deadlines. Without all the required documents submitted at the time of application, your application will not be processed and we cannot accept responsibility for late or missed deadlines. Incomplete applications will not be considered.  If you have any queries regarding making an application, please contact our admissions team.  

Equality, Diversity and Inclusion  

Equality, diversity and inclusion is fundamental to the success of The University of Manchester, and is at the heart of all of our activities. The full Equality, diversity and inclusion statement can be found on the website. 

Biological Sciences (4) Computer Science (8) Mathematics (25) Medicine (26)

Funding Notes

Studentship funding is for 4 years and covers tuition fees and an annual stipend. This does not include any costs associated with relocation. 


Open Days


Register your interest for this project



Where will I study?

Faculty of Biology, Medicine and Health

Tackle real world challenges, make a difference, and elevate your career with postgraduate research in the Faculty of Biology, Medicine and Health at Manchester. From biochemistry to neuroscience, cancer sciences to medicine, audiology to mental health and everything in between, we offer a wide range of postgraduate research projects, programmes and funding which will allow you to immerse yourself in an area of research you’re passionate about.

Why study at Faculty of Biology, Medicine and Health?

Ranked the best place to live in the UK (The Economist Global Liveability Index, 2022), Manchester boasts world-class culture, iconic sports, a thriving music and food scene, and much more. It's not just a place to research, it's a place to call home.

Experience PhD life as part of a diverse postgraduate research community of more than 1,000 postgraduate researchers at the 29th most international university in the world (Times Higher Education, 2023).

With 93% of research activity at the University rated as 'world-leading' or 'internationally excellent' (Research Excellence Framework, 2021), you'll get the chance to have an impact on global health and science challenges.

1000+

postgraduate students

221

PhDs

6

ranked in UK - QS (2025)

Manchester  United Kingdom

main campus

Upcoming Open Days & Webinars


About Faculty of Biology, Medicine and Health

At Manchester, postgraduate researchers are at the heart of our mission to tackle pressing global challenges in biological, medical and healthcare sciences - and you could be too.

By choosing Manchester for your postgraduate research, you’ll be joining a university with an exceptional research reputation, where 93% of research is world-leading or internationally excellent (REF, 2021) and where your work will have real-world impact.

You’ll research in world-class facilities alongside leading experts at the forefront of innovation, collaborating across disciplines to pioneer new treatments, advance scientific knowledge, and improve healthcare globally.

Supported by our dedicated Doctoral Academy and strong industry links, you'll experience PhD life in a vibrant, welcoming and diverse postgraduate research community.

And you’ll leave with the specialist knowledge, research experience and transferable skills that will shape your future in academia, research or industry.





Main campus

The University of Manchester

Manchester

North West

United Kingdom

PhD saved sucessfully

(International Partnership Studentship) Using white matter network alterations relating to stroke risk to predict cognitive and health outcomes

The project aims to investigate how age-related changes in brain white matter impact upon cognitive and health outcomes. Using advanced software and MRI data from the UK Biobank, the researchers will create effective cross-sectional and longitudinal models of how white matter abnormalities predict cognitive function. Read more
More details

(MB-PhD) Gene regulatory networks driving metastatic progression in oesophageal adenocarcinoma

Oesophageal adenocarcinoma (OAC) incidence is increasing and yet survival rates remain very poor. There are limited treatment options, especially for metastatic disease, which is especially problematic as patients usually present with late stage disease. Read more
More details

(MB-PhD) MYST Histone Acetyltransferases as Therapeutic Targets in Acute Myeloid Leukaemia

Cytotoxic chemotherapy has been the standard of care for treatment of acute myeloid leukaemia (AML) for the last 50 years. Unfortunately, more often than not, it fails to cure patients, and the 5 years survival rate for all-comers with AML is only around 20%. Read more
More details

(MB-PhD)Immunomodulation in multiple myeloma

Multiple myeloma is a devastating B-cell malignancy for which there is no cure. The development of immunomodulatory drugs (IMiDs) has proved transformative to multiple myeloma care, however, their remain unanswered questions related to the mechanism of action of this important drug class. Read more
More details
Last chance to apply

(MCRC Clinical) The VIGILANCE study: developing imaging and circulating biomarkers towards personalised radiotherapy in locally advanced lung cancer

Lung cancer is the leading cause of cancer mortality worldwide. Non-small-cell lung cancer (NSCLC) is the most common type. One-fifth of patients present with stage 3 or locally advanced (LA) disease, equating to approximately 9,000 patients annually in England. Read more
More details
Last chance to apply

(MRC DTP CASE) Developing a cortical organoid model of genetic autism to understand early brain development

Neurodevelopmental conditions including autism and ADHD affect 4-8% of the paediatric population. These conditions present in the preschool period, are highly heritable and can severely affect quality of life, academic and occupational functioning. Read more
More details
Last chance to apply

(MRC DTP CASE) Developing new acute treatments for stroke by targeting the cytokine interleukin-1

Acute brain injury caused by stroke is a leading cause of global death and disability. Despite decades of research there is still no widely available effective treatment for stroke, and it remains an area of significant unmet need. Read more
More details
Last chance to apply

(MRC DTP CASE) Drug Binding on human G-Protein Coupled Receptors under Tension-Altered Biomechanics in Diseases

Integral membrane proteins (MPs) constitute a significant part of the genome and are targets of ~30% of therapeutics. However, structural and functional understanding of these proteins often lags behind that of their soluble counterparts. Read more
More details
Last chance to apply

(MRC DTP) Circadian mechanisms in psoriasis: translating genomic and computational analysis to clinical care.

Despite numerous lines of evidence supporting a role for the circadian clock regulating multiple immunological axes, the dominant cell type driving rhythmic disease expression in psoriasis remains undetermined and there has been no progress on time-of-day regulation of psoriasis. Read more
More details
Last chance to apply

(MRC DTP) Combinatorial targeting of multiple disease mechanisms in drug-resistant epilepsy using microRNA inhibitors

Epilepsy is one of the most common chronic neurological diseases, affecting ~70 million people worldwide. Epilepsy is characterised by susceptibility to spontaneous seizures, and can also include challenges with cognition, sleep and mental health. Read more
More details
Last chance to apply

(MRC DTP) Combining Randomised Controlled Trials and Real-World Evidence to Optimise the Therapeutic Ratio in Radiotherapy

Radiotherapy (using radiation to destroy a tumour) is an important and effective treatment for cancer. Treatments are planned on medical images to precisely shape the regions of high radiation dose to the tumours of each patient. Read more